Corticosteroids differ in their ability to produce an IOP response
Miola A, Alvarez-Villalobos NA, Ruiz-Hernandez FG, De Filippis E, Veldic M, Prieto ML, et al
According to the World Health Organization (WHO), over 422 million people globally live with diabetes, while the Institute for Health Metrics and Evaluation (IHME) reports obesity prevalence has doubled since 1990, significantly increasing demand for GLP-1 analogues for effective metabolic disorder management
[DOI] [PubMed] [Google Scholar] 184.Stile RA, Healy KE
PRINCETON, N.J., June 24, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company trusted by millions, today announced the launch of its free GLP-1 Companion program, now available at no cost to anyone taking a GLP-1 medication, regardless of provider